Apimeds Pharmaceuticals US, Inc (AMEX: APUS) Stock Competitors & Peer Comparison
See APUS's competitors and their performance on the AMEX and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for APUS and its AMEX peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| APUS | $0.66 | +3.61% | 861.3K | -0.25 | -$2.71 | N/A |
| TAK | $16.87 | -2.09% | 53.6B | 12.12 | $1.39 | +3.67% |
| HLN | $9.85 | -0.71% | 43.4B | 24.64 | $0.40 | +1.94% |
| TEVA | $30.15 | -3.83% | 35.1B | 10.29 | $2.93 | N/A |
| VTRS | $17.01 | -3.30% | 19.8B | 6.94 | $2.45 | +2.74% |
| ITCI | $131.87 | +0.00% | 14B | -180.64 | -$0.73 | N/A |
| ELAN | $25.34 | -0.55% | 12.7B | 25.86 | $0.98 | N/A |
| CTLT | $63.48 | +0.00% | 11.5B | -27.84 | -$2.28 | N/A |
| RDY | $11.38 | -9.39% | 9.5B | 18.69 | $0.61 | +0.51% |
| LNTH | $104.61 | -3.09% | 6.8B | 17.52 | $5.97 | N/A |
Stock Comparison
Takeda Pharmaceutical Company Limited (NYSE: TAK)
APUS vs TAK Comparison July 2026
Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APUS stands at 861.3K. In comparison, TAK has a market cap of 53.6B. Regarding current trading prices, APUS is priced at $0.66 on the AMEX, while TAK trades at $16.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APUS currently has a P/E ratio of -0.25, whereas TAK's P/E ratio is 12.12. In terms of profitability, APUS's ROE is -0.55%, compared to TAK's ROE of +0.03%. Regarding short-term risk, APUS is more volatile compared to TAK. This indicates higher risk in terms of short-term price fluctuations for APUS.Check TAK's competition here
Haleon plc (NYSE: HLN)
APUS vs HLN Comparison July 2026
Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APUS stands at 861.3K. In comparison, HLN has a market cap of 43.4B. Regarding current trading prices, APUS is priced at $0.66 on the AMEX, while HLN trades at $9.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APUS currently has a P/E ratio of -0.25, whereas HLN's P/E ratio is 24.64. In terms of profitability, APUS's ROE is -0.55%, compared to HLN's ROE of +0.13%. Regarding short-term risk, APUS is more volatile compared to HLN. This indicates higher risk in terms of short-term price fluctuations for APUS.Check HLN's competition here
Teva Pharmaceutical Industries Limited (NYSE: TEVA)
APUS vs TEVA Comparison July 2026
Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APUS stands at 861.3K. In comparison, TEVA has a market cap of 35.1B. Regarding current trading prices, APUS is priced at $0.66 on the AMEX, while TEVA trades at $30.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APUS currently has a P/E ratio of -0.25, whereas TEVA's P/E ratio is 10.29. In terms of profitability, APUS's ROE is -0.55%, compared to TEVA's ROE of +0.21%. Regarding short-term risk, APUS is more volatile compared to TEVA. This indicates higher risk in terms of short-term price fluctuations for APUS.Check TEVA's competition here
Viatris Inc. (NASDAQ: VTRS)
APUS vs VTRS Comparison July 2026
Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APUS stands at 861.3K. In comparison, VTRS has a market cap of 19.8B. Regarding current trading prices, APUS is priced at $0.66 on the AMEX, while VTRS trades at $17.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APUS currently has a P/E ratio of -0.25, whereas VTRS's P/E ratio is 6.94. In terms of profitability, APUS's ROE is -0.55%, compared to VTRS's ROE of -0.02%. Regarding short-term risk, APUS is more volatile compared to VTRS. This indicates higher risk in terms of short-term price fluctuations for APUS.Check VTRS's competition here
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI)
APUS vs ITCI Comparison July 2026
Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APUS stands at 861.3K. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, APUS is priced at $0.66 on the AMEX, while ITCI trades at $131.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APUS currently has a P/E ratio of -0.25, whereas ITCI's P/E ratio is -180.64. In terms of profitability, APUS's ROE is -0.55%, compared to ITCI's ROE of -0.09%. Regarding short-term risk, APUS is more volatile compared to ITCI. This indicates higher risk in terms of short-term price fluctuations for APUS.Check ITCI's competition here
Elanco Animal Health Incorporated (NYSE: ELAN)
APUS vs ELAN Comparison July 2026
Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APUS stands at 861.3K. In comparison, ELAN has a market cap of 12.7B. Regarding current trading prices, APUS is priced at $0.66 on the AMEX, while ELAN trades at $25.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APUS currently has a P/E ratio of -0.25, whereas ELAN's P/E ratio is 25.86. In terms of profitability, APUS's ROE is -0.55%, compared to ELAN's ROE of -0.04%. Regarding short-term risk, APUS is more volatile compared to ELAN. This indicates higher risk in terms of short-term price fluctuations for APUS.Check ELAN's competition here
Catalent, Inc. (NYSE: CTLT)
APUS vs CTLT Comparison July 2026
Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APUS stands at 861.3K. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, APUS is priced at $0.66 on the AMEX, while CTLT trades at $63.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APUS currently has a P/E ratio of -0.25, whereas CTLT's P/E ratio is -27.84. In terms of profitability, APUS's ROE is -0.55%, compared to CTLT's ROE of -0.25%. Regarding short-term risk, APUS is more volatile compared to CTLT. This indicates higher risk in terms of short-term price fluctuations for APUS.Check CTLT's competition here
Dr. Reddy's Laboratories Limited (NYSE: RDY)
APUS vs RDY Comparison July 2026
Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APUS stands at 861.3K. In comparison, RDY has a market cap of 9.5B. Regarding current trading prices, APUS is priced at $0.66 on the AMEX, while RDY trades at $11.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APUS currently has a P/E ratio of -0.25, whereas RDY's P/E ratio is 18.69. In terms of profitability, APUS's ROE is -0.55%, compared to RDY's ROE of +0.12%. Regarding short-term risk, APUS is more volatile compared to RDY. This indicates higher risk in terms of short-term price fluctuations for APUS.Check RDY's competition here
Lantheus Holdings, Inc. (NASDAQ: LNTH)
APUS vs LNTH Comparison July 2026
Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APUS stands at 861.3K. In comparison, LNTH has a market cap of 6.8B. Regarding current trading prices, APUS is priced at $0.66 on the AMEX, while LNTH trades at $104.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APUS currently has a P/E ratio of -0.25, whereas LNTH's P/E ratio is 17.52. In terms of profitability, APUS's ROE is -0.55%, compared to LNTH's ROE of +0.24%. Regarding short-term risk, APUS is more volatile compared to LNTH. This indicates higher risk in terms of short-term price fluctuations for APUS.Check LNTH's competition here
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX)
APUS vs AMRX Comparison July 2026
Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APUS stands at 861.3K. In comparison, AMRX has a market cap of 5.7B. Regarding current trading prices, APUS is priced at $0.66 on the AMEX, while AMRX trades at $17.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APUS currently has a P/E ratio of -0.25, whereas AMRX's P/E ratio is 19.72. In terms of profitability, APUS's ROE is -0.55%, compared to AMRX's ROE of -1.45%. Regarding short-term risk, APUS is more volatile compared to AMRX. This indicates higher risk in terms of short-term price fluctuations for APUS.Check AMRX's competition here
Indivior Pharmaceuticals Inc (NASDAQ: INDV)
APUS vs INDV Comparison July 2026
Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APUS stands at 861.3K. In comparison, INDV has a market cap of 5B. Regarding current trading prices, APUS is priced at $0.66 on the AMEX, while INDV trades at $40.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APUS currently has a P/E ratio of -0.25, whereas INDV's P/E ratio is 13.44. In terms of profitability, APUS's ROE is -0.55%, compared to INDV's ROE of -1.42%. Regarding short-term risk, APUS is more volatile compared to INDV. This indicates higher risk in terms of short-term price fluctuations for APUS.Check INDV's competition here
Regencell Bioscience Holdings Limited (NASDAQ: RGC)
APUS vs RGC Comparison July 2026
Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APUS stands at 861.3K. In comparison, RGC has a market cap of 3B. Regarding current trading prices, APUS is priced at $0.66 on the AMEX, while RGC trades at $5.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APUS currently has a P/E ratio of -0.25, whereas RGC's P/E ratio is -421.13. In terms of profitability, APUS's ROE is -0.55%, compared to RGC's ROE of -2.32%. Regarding short-term risk, APUS is less volatile compared to RGC. This indicates lower risk in terms of short-term price fluctuations for APUS.Check RGC's competition here
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN)
APUS vs SUPN Comparison July 2026
Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APUS stands at 861.3K. In comparison, SUPN has a market cap of 2.7B. Regarding current trading prices, APUS is priced at $0.66 on the AMEX, while SUPN trades at $46.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APUS currently has a P/E ratio of -0.25, whereas SUPN's P/E ratio is 13.69. In terms of profitability, APUS's ROE is -0.55%, compared to SUPN's ROE of -0.03%. Regarding short-term risk, APUS is more volatile compared to SUPN. This indicates higher risk in terms of short-term price fluctuations for APUS.Check SUPN's competition here
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH)
APUS vs DCPH Comparison July 2026
Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APUS stands at 861.3K. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, APUS is priced at $0.66 on the AMEX, while DCPH trades at $25.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APUS currently has a P/E ratio of -0.25, whereas DCPH's P/E ratio is -11.58. In terms of profitability, APUS's ROE is -0.55%, compared to DCPH's ROE of -0.56%. Regarding short-term risk, APUS is more volatile compared to DCPH. This indicates higher risk in terms of short-term price fluctuations for APUS.Check DCPH's competition here
Avadel Pharmaceuticals plc (NASDAQ: AVDL)
APUS vs AVDL Comparison July 2026
Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APUS stands at 861.3K. In comparison, AVDL has a market cap of 2.1B. Regarding current trading prices, APUS is priced at $0.66 on the AMEX, while AVDL trades at $21.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APUS currently has a P/E ratio of -0.25, whereas AVDL's P/E ratio is -1082.00. In terms of profitability, APUS's ROE is -0.55%, compared to AVDL's ROE of +0.05%. Regarding short-term risk, APUS is more volatile compared to AVDL. This indicates higher risk in terms of short-term price fluctuations for APUS.Check AVDL's competition here
HUTCHMED (China) Limited (NASDAQ: HCM)
APUS vs HCM Comparison July 2026
Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APUS stands at 861.3K. In comparison, HCM has a market cap of 1.9B. Regarding current trading prices, APUS is priced at $0.66 on the AMEX, while HCM trades at $11.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APUS currently has a P/E ratio of -0.25, whereas HCM's P/E ratio is 4.17. In terms of profitability, APUS's ROE is -0.55%, compared to HCM's ROE of +0.37%. Regarding short-term risk, APUS is more volatile compared to HCM. This indicates higher risk in terms of short-term price fluctuations for APUS.Check HCM's competition here
Embecta Corp. (NASDAQ: EMBCV)
APUS vs EMBCV Comparison July 2026
Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APUS stands at 861.3K. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, APUS is priced at $0.66 on the AMEX, while EMBCV trades at $33.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APUS currently has a P/E ratio of -0.25, whereas EMBCV's P/E ratio is N/A. In terms of profitability, APUS's ROE is -0.55%, compared to EMBCV's ROE of -0.23%. Regarding short-term risk, APUS is less volatile compared to EMBCV. This indicates lower risk in terms of short-term price fluctuations for APUS.Check EMBCV's competition here
Dynavax Technologies Corporation (NASDAQ: DVAX)
APUS vs DVAX Comparison July 2026
Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APUS stands at 861.3K. In comparison, DVAX has a market cap of 1.8B. Regarding current trading prices, APUS is priced at $0.66 on the AMEX, while DVAX trades at $15.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APUS currently has a P/E ratio of -0.25, whereas DVAX's P/E ratio is -41.89. In terms of profitability, APUS's ROE is -0.55%, compared to DVAX's ROE of -0.10%. Regarding short-term risk, APUS is more volatile compared to DVAX. This indicates higher risk in terms of short-term price fluctuations for APUS.Check DVAX's competition here
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP)
APUS vs ANIP Comparison July 2026
Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APUS stands at 861.3K. In comparison, ANIP has a market cap of 1.8B. Regarding current trading prices, APUS is priced at $0.66 on the AMEX, while ANIP trades at $77.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APUS currently has a P/E ratio of -0.25, whereas ANIP's P/E ratio is 9.44. In terms of profitability, APUS's ROE is -0.55%, compared to ANIP's ROE of +0.17%. Regarding short-term risk, APUS is more volatile compared to ANIP. This indicates higher risk in terms of short-term price fluctuations for APUS.Check ANIP's competition here
Bausch Health Companies Inc. (NYSE: BHC)
APUS vs BHC Comparison July 2026
Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APUS stands at 861.3K. In comparison, BHC has a market cap of 1.7B. Regarding current trading prices, APUS is priced at $0.66 on the AMEX, while BHC trades at $4.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APUS currently has a P/E ratio of -0.25, whereas BHC's P/E ratio is 1.16. In terms of profitability, APUS's ROE is -0.55%, compared to BHC's ROE of +1.21%. Regarding short-term risk, APUS is more volatile compared to BHC. This indicates higher risk in terms of short-term price fluctuations for APUS.Check BHC's competition here
Taro Pharmaceutical Industries Ltd. (NYSE: TARO)
APUS vs TARO Comparison July 2026
Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APUS stands at 861.3K. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, APUS is priced at $0.66 on the AMEX, while TARO trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APUS currently has a P/E ratio of -0.25, whereas TARO's P/E ratio is 30.05. In terms of profitability, APUS's ROE is -0.55%, compared to TARO's ROE of +0.03%. Regarding short-term risk, APUS is more volatile compared to TARO. This indicates higher risk in terms of short-term price fluctuations for APUS.Check TARO's competition here
Harrow Health, Inc. (NASDAQ: HROW)
APUS vs HROW Comparison July 2026
Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APUS stands at 861.3K. In comparison, HROW has a market cap of 1.6B. Regarding current trading prices, APUS is priced at $0.66 on the AMEX, while HROW trades at $42.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APUS currently has a P/E ratio of -0.25, whereas HROW's P/E ratio is 475.89. In terms of profitability, APUS's ROE is -0.55%, compared to HROW's ROE of -0.34%. Regarding short-term risk, APUS is more volatile compared to HROW. This indicates higher risk in terms of short-term price fluctuations for APUS.Check HROW's competition here
Alvotech (NASDAQ: ALVOW)
APUS vs ALVOW Comparison July 2026
Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APUS stands at 861.3K. In comparison, ALVOW has a market cap of 1.5B. Regarding current trading prices, APUS is priced at $0.66 on the AMEX, while ALVOW trades at $0.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APUS currently has a P/E ratio of -0.25, whereas ALVOW's P/E ratio is 32.03. In terms of profitability, APUS's ROE is -0.55%, compared to ALVOW's ROE of +0.35%. Regarding short-term risk, APUS is more volatile compared to ALVOW. This indicates higher risk in terms of short-term price fluctuations for APUS.Check ALVOW's competition here
Perrigo Company plc (NYSE: PRGO)
APUS vs PRGO Comparison July 2026
Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APUS stands at 861.3K. In comparison, PRGO has a market cap of 1.4B. Regarding current trading prices, APUS is priced at $0.66 on the AMEX, while PRGO trades at $10.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APUS currently has a P/E ratio of -0.25, whereas PRGO's P/E ratio is 4.07. In terms of profitability, APUS's ROE is -0.55%, compared to PRGO's ROE of -0.51%. Regarding short-term risk, APUS is more volatile compared to PRGO. This indicates higher risk in terms of short-term price fluctuations for APUS.Check PRGO's competition here
Phibro Animal Health Corporation (NASDAQ: PAHC)
APUS vs PAHC Comparison July 2026
Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APUS stands at 861.3K. In comparison, PAHC has a market cap of 1.4B. Regarding current trading prices, APUS is priced at $0.66 on the AMEX, while PAHC trades at $33.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APUS currently has a P/E ratio of -0.25, whereas PAHC's P/E ratio is 11.54. In terms of profitability, APUS's ROE is -0.55%, compared to PAHC's ROE of +0.29%. Regarding short-term risk, APUS is more volatile compared to PAHC. This indicates higher risk in terms of short-term price fluctuations for APUS.Check PAHC's competition here
Eton Pharmaceuticals, Inc. (NASDAQ: ETON)
APUS vs ETON Comparison July 2026
Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APUS stands at 861.3K. In comparison, ETON has a market cap of 1.2B. Regarding current trading prices, APUS is priced at $0.66 on the AMEX, while ETON trades at $43.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APUS currently has a P/E ratio of -0.25, whereas ETON's P/E ratio is -622.57. In terms of profitability, APUS's ROE is -0.55%, compared to ETON's ROE of -0.06%. Regarding short-term risk, APUS is more volatile compared to ETON. This indicates higher risk in terms of short-term price fluctuations for APUS.Check ETON's competition here
Collegium Pharmaceutical, Inc. (NASDAQ: COLL)
APUS vs COLL Comparison July 2026
Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APUS stands at 861.3K. In comparison, COLL has a market cap of 1.1B. Regarding current trading prices, APUS is priced at $0.66 on the AMEX, while COLL trades at $34.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APUS currently has a P/E ratio of -0.25, whereas COLL's P/E ratio is 4.49. In terms of profitability, APUS's ROE is -0.55%, compared to COLL's ROE of +0.27%. Regarding short-term risk, APUS is more volatile compared to COLL. This indicates higher risk in terms of short-term price fluctuations for APUS.Check COLL's competition here
Alvotech (NASDAQ: ALVO)
APUS vs ALVO Comparison July 2026
Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APUS stands at 861.3K. In comparison, ALVO has a market cap of 1.1B. Regarding current trading prices, APUS is priced at $0.66 on the AMEX, while ALVO trades at $3.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APUS currently has a P/E ratio of -0.25, whereas ALVO's P/E ratio is -9.38. In terms of profitability, APUS's ROE is -0.55%, compared to ALVO's ROE of +0.35%. Regarding short-term risk, APUS is less volatile compared to ALVO. This indicates lower risk in terms of short-term price fluctuations for APUS.Check ALVO's competition here
Cronos Group Inc. (NASDAQ: CRON)
APUS vs CRON Comparison July 2026
Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APUS stands at 861.3K. In comparison, CRON has a market cap of 1B. Regarding current trading prices, APUS is priced at $0.66 on the AMEX, while CRON trades at $2.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APUS currently has a P/E ratio of -0.25, whereas CRON's P/E ratio is -112.55. In terms of profitability, APUS's ROE is -0.55%, compared to CRON's ROE of -0.00%. Regarding short-term risk, APUS is more volatile compared to CRON. This indicates higher risk in terms of short-term price fluctuations for APUS.Check CRON's competition here
Pacira BioSciences, Inc. (NASDAQ: PCRX)
APUS vs PCRX Comparison July 2026
Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APUS stands at 861.3K. In comparison, PCRX has a market cap of 1B. Regarding current trading prices, APUS is priced at $0.66 on the AMEX, while PCRX trades at $25.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APUS currently has a P/E ratio of -0.25, whereas PCRX's P/E ratio is 9.80. In terms of profitability, APUS's ROE is -0.55%, compared to PCRX's ROE of +0.01%. Regarding short-term risk, APUS is more volatile compared to PCRX. This indicates higher risk in terms of short-term price fluctuations for APUS.Check PCRX's competition here
PetIQ, Inc. (NASDAQ: PETQ)
APUS vs PETQ Comparison July 2026
Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APUS stands at 861.3K. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, APUS is priced at $0.66 on the AMEX, while PETQ trades at $30.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APUS currently has a P/E ratio of -0.25, whereas PETQ's P/E ratio is 83.73. In terms of profitability, APUS's ROE is -0.55%, compared to PETQ's ROE of +0.01%. Regarding short-term risk, APUS is more volatile compared to PETQ. This indicates higher risk in terms of short-term price fluctuations for APUS.Check PETQ's competition here
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH)
APUS vs AMPH Comparison July 2026
Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APUS stands at 861.3K. In comparison, AMPH has a market cap of 851M. Regarding current trading prices, APUS is priced at $0.66 on the AMEX, while AMPH trades at $19.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APUS currently has a P/E ratio of -0.25, whereas AMPH's P/E ratio is 6.59. In terms of profitability, APUS's ROE is -0.55%, compared to AMPH's ROE of +0.10%. Regarding short-term risk, APUS is more volatile compared to AMPH. This indicates higher risk in terms of short-term price fluctuations for APUS.Check AMPH's competition here
Evotec SE (NASDAQ: EVO)
APUS vs EVO Comparison July 2026
Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APUS stands at 861.3K. In comparison, EVO has a market cap of 692.6M. Regarding current trading prices, APUS is priced at $0.66 on the AMEX, while EVO trades at $1.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APUS currently has a P/E ratio of -0.25, whereas EVO's P/E ratio is -2.75. In terms of profitability, APUS's ROE is -0.55%, compared to EVO's ROE of -0.24%. Regarding short-term risk, APUS is more volatile compared to EVO. This indicates higher risk in terms of short-term price fluctuations for APUS.Check EVO's competition here
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD)
APUS vs IRWD Comparison July 2026
Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APUS stands at 861.3K. In comparison, IRWD has a market cap of 638.7M. Regarding current trading prices, APUS is priced at $0.66 on the AMEX, while IRWD trades at $3.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APUS currently has a P/E ratio of -0.25, whereas IRWD's P/E ratio is 6.36. In terms of profitability, APUS's ROE is -0.55%, compared to IRWD's ROE of -0.39%. Regarding short-term risk, APUS is more volatile compared to IRWD. This indicates higher risk in terms of short-term price fluctuations for APUS.Check IRWD's competition here
BioDelivery Sciences International, Inc. (NASDAQ: BDSI)
APUS vs BDSI Comparison July 2026
Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APUS stands at 861.3K. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, APUS is priced at $0.66 on the AMEX, while BDSI trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APUS currently has a P/E ratio of -0.25, whereas BDSI's P/E ratio is 6.82. In terms of profitability, APUS's ROE is -0.55%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, APUS is more volatile compared to BDSI. This indicates higher risk in terms of short-term price fluctuations for APUS.Check BDSI's competition here
Tilray Brands, Inc. (NASDAQ: TLRY)
APUS vs TLRY Comparison July 2026
Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APUS stands at 861.3K. In comparison, TLRY has a market cap of 499.2M. Regarding current trading prices, APUS is priced at $0.66 on the AMEX, while TLRY trades at $4.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APUS currently has a P/E ratio of -0.25, whereas TLRY's P/E ratio is -6.56. In terms of profitability, APUS's ROE is -0.55%, compared to TLRY's ROE of -0.93%. Regarding short-term risk, APUS is more volatile compared to TLRY. This indicates higher risk in terms of short-term price fluctuations for APUS.Check TLRY's competition here
Kamada Ltd. (NASDAQ: KMDA)
APUS vs KMDA Comparison July 2026
Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APUS stands at 861.3K. In comparison, KMDA has a market cap of 404.4M. Regarding current trading prices, APUS is priced at $0.66 on the AMEX, while KMDA trades at $7.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APUS currently has a P/E ratio of -0.25, whereas KMDA's P/E ratio is 20.03. In terms of profitability, APUS's ROE is -0.55%, compared to KMDA's ROE of +0.08%. Regarding short-term risk, APUS is more volatile compared to KMDA. This indicates higher risk in terms of short-term price fluctuations for APUS.Check KMDA's competition here
Aquestive Therapeutics, Inc. (NASDAQ: AQST)
APUS vs AQST Comparison July 2026
Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APUS stands at 861.3K. In comparison, AQST has a market cap of 391.3M. Regarding current trading prices, APUS is priced at $0.66 on the AMEX, while AQST trades at $3.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APUS currently has a P/E ratio of -0.25, whereas AQST's P/E ratio is -6.46. In terms of profitability, APUS's ROE is -0.55%, compared to AQST's ROE of +1.91%. Regarding short-term risk, APUS is more volatile compared to AQST. This indicates higher risk in terms of short-term price fluctuations for APUS.Check AQST's competition here
Evolus, Inc. (NASDAQ: EOLS)
APUS vs EOLS Comparison July 2026
Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APUS stands at 861.3K. In comparison, EOLS has a market cap of 387.9M. Regarding current trading prices, APUS is priced at $0.66 on the AMEX, while EOLS trades at $5.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APUS currently has a P/E ratio of -0.25, whereas EOLS's P/E ratio is -13.52. In terms of profitability, APUS's ROE is -0.55%, compared to EOLS's ROE of +1.75%. Regarding short-term risk, APUS is more volatile compared to EOLS. This indicates higher risk in terms of short-term price fluctuations for APUS.Check EOLS's competition here
Canopy Growth Corporation (NASDAQ: CGC)
APUS vs CGC Comparison July 2026
Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APUS stands at 861.3K. In comparison, CGC has a market cap of 384.2M. Regarding current trading prices, APUS is priced at $0.66 on the AMEX, while CGC trades at $0.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APUS currently has a P/E ratio of -0.25, whereas CGC's P/E ratio is -0.55. In terms of profitability, APUS's ROE is -0.55%, compared to CGC's ROE of -0.39%. Regarding short-term risk, APUS is more volatile compared to CGC. This indicates higher risk in terms of short-term price fluctuations for APUS.Check CGC's competition here
Organogenesis Holdings Inc. (NASDAQ: ORGO)
APUS vs ORGO Comparison July 2026
Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APUS stands at 861.3K. In comparison, ORGO has a market cap of 346.1M. Regarding current trading prices, APUS is priced at $0.66 on the AMEX, while ORGO trades at $2.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APUS currently has a P/E ratio of -0.25, whereas ORGO's P/E ratio is 89.67. In terms of profitability, APUS's ROE is -0.55%, compared to ORGO's ROE of -0.00%. Regarding short-term risk, APUS is less volatile compared to ORGO. This indicates lower risk in terms of short-term price fluctuations for APUS.Check ORGO's competition here
SNDL Inc. (NASDAQ: SNDL)
APUS vs SNDL Comparison July 2026
Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APUS stands at 861.3K. In comparison, SNDL has a market cap of 330.6M. Regarding current trading prices, APUS is priced at $0.66 on the AMEX, while SNDL trades at $1.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APUS currently has a P/E ratio of -0.25, whereas SNDL's P/E ratio is -42.33. In terms of profitability, APUS's ROE is -0.55%, compared to SNDL's ROE of -0.01%. Regarding short-term risk, APUS is more volatile compared to SNDL. This indicates higher risk in terms of short-term price fluctuations for APUS.Check SNDL's competition here
Alimera Sciences, Inc. (NASDAQ: ALIM)
APUS vs ALIM Comparison July 2026
Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APUS stands at 861.3K. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, APUS is priced at $0.66 on the AMEX, while ALIM trades at $5.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APUS currently has a P/E ratio of -0.25, whereas ALIM's P/E ratio is 5.28. In terms of profitability, APUS's ROE is -0.55%, compared to ALIM's ROE of -1.59%. Regarding short-term risk, APUS is more volatile compared to ALIM. This indicates higher risk in terms of short-term price fluctuations for APUS.Check ALIM's competition here
Alpha Teknova, Inc. (NASDAQ: TKNO)
APUS vs TKNO Comparison July 2026
Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APUS stands at 861.3K. In comparison, TKNO has a market cap of 280.9M. Regarding current trading prices, APUS is priced at $0.66 on the AMEX, while TKNO trades at $5.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APUS currently has a P/E ratio of -0.25, whereas TKNO's P/E ratio is -16.37. In terms of profitability, APUS's ROE is -0.55%, compared to TKNO's ROE of -0.24%. Regarding short-term risk, APUS is more volatile compared to TKNO. This indicates higher risk in terms of short-term price fluctuations for APUS.Check TKNO's competition here
Landec Corporation (NASDAQ: LNDC)
APUS vs LNDC Comparison July 2026
Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APUS stands at 861.3K. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, APUS is priced at $0.66 on the AMEX, while LNDC trades at $8.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APUS currently has a P/E ratio of -0.25, whereas LNDC's P/E ratio is -4.04. In terms of profitability, APUS's ROE is -0.55%, compared to LNDC's ROE of -9.05%. Regarding short-term risk, APUS is more volatile compared to LNDC. This indicates higher risk in terms of short-term price fluctuations for APUS.Check LNDC's competition here
SIGA Technologies, Inc. (NASDAQ: SIGA)
APUS vs SIGA Comparison July 2026
Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APUS stands at 861.3K. In comparison, SIGA has a market cap of 243.1M. Regarding current trading prices, APUS is priced at $0.66 on the AMEX, while SIGA trades at $3.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APUS currently has a P/E ratio of -0.25, whereas SIGA's P/E ratio is 12.56. In terms of profitability, APUS's ROE is -0.55%, compared to SIGA's ROE of +0.11%. Regarding short-term risk, APUS is more volatile compared to SIGA. This indicates higher risk in terms of short-term price fluctuations for APUS.Check SIGA's competition here
Shineco, Inc. (NASDAQ: TYHT)
APUS vs TYHT Comparison July 2026
Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APUS stands at 861.3K. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, APUS is priced at $0.66 on the AMEX, while TYHT trades at $11.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APUS currently has a P/E ratio of -0.25, whereas TYHT's P/E ratio is -1.61. In terms of profitability, APUS's ROE is -0.55%, compared to TYHT's ROE of -0.57%. Regarding short-term risk, APUS is more volatile compared to TYHT. This indicates higher risk in terms of short-term price fluctuations for APUS.Check TYHT's competition here
Journey Medical Corporation (NASDAQ: DERM)
APUS vs DERM Comparison July 2026
Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APUS stands at 861.3K. In comparison, DERM has a market cap of 196M. Regarding current trading prices, APUS is priced at $0.66 on the AMEX, while DERM trades at $7.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APUS currently has a P/E ratio of -0.25, whereas DERM's P/E ratio is -19.24. In terms of profitability, APUS's ROE is -0.55%, compared to DERM's ROE of -0.36%. Regarding short-term risk, APUS is more volatile compared to DERM. This indicates higher risk in terms of short-term price fluctuations for APUS.Check DERM's competition here
Embecta Corp. (NASDAQ: EMBC)
APUS vs EMBC Comparison July 2026
Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APUS stands at 861.3K. In comparison, EMBC has a market cap of 192.8M. Regarding current trading prices, APUS is priced at $0.66 on the AMEX, while EMBC trades at $3.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APUS currently has a P/E ratio of -0.25, whereas EMBC's P/E ratio is 1.25. In terms of profitability, APUS's ROE is -0.55%, compared to EMBC's ROE of -0.17%. Regarding short-term risk, APUS is more volatile compared to EMBC. This indicates higher risk in terms of short-term price fluctuations for APUS.Check EMBC's competition here
Recro Pharma, Inc. (NASDAQ: REPH)
APUS vs REPH Comparison July 2026
Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APUS stands at 861.3K. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, APUS is priced at $0.66 on the AMEX, while REPH trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APUS currently has a P/E ratio of -0.25, whereas REPH's P/E ratio is -8.04. In terms of profitability, APUS's ROE is -0.55%, compared to REPH's ROE of -0.22%. Regarding short-term risk, APUS is more volatile compared to REPH. This indicates higher risk in terms of short-term price fluctuations for APUS.Check REPH's competition here
Lifecore Biomedical, Inc. (NASDAQ: LFCR)
APUS vs LFCR Comparison July 2026
Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APUS stands at 861.3K. In comparison, LFCR has a market cap of 171.8M. Regarding current trading prices, APUS is priced at $0.66 on the AMEX, while LFCR trades at $4.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APUS currently has a P/E ratio of -0.25, whereas LFCR's P/E ratio is -4.67. In terms of profitability, APUS's ROE is -0.55%, compared to LFCR's ROE of -1.76%. Regarding short-term risk, APUS is more volatile compared to LFCR. This indicates higher risk in terms of short-term price fluctuations for APUS.Check LFCR's competition here
Aurora Cannabis Inc. (NASDAQ: ACB)
APUS vs ACB Comparison July 2026
Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APUS stands at 861.3K. In comparison, ACB has a market cap of 164.8M. Regarding current trading prices, APUS is priced at $0.66 on the AMEX, while ACB trades at $2.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APUS currently has a P/E ratio of -0.25, whereas ACB's P/E ratio is 44.33. In terms of profitability, APUS's ROE is -0.55%, compared to ACB's ROE of -0.14%. Regarding short-term risk, APUS is more volatile compared to ACB. This indicates higher risk in terms of short-term price fluctuations for APUS.Check ACB's competition here
Theratechnologies Inc. (NASDAQ: THTX)
APUS vs THTX Comparison July 2026
Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APUS stands at 861.3K. In comparison, THTX has a market cap of 155.9M. Regarding current trading prices, APUS is priced at $0.66 on the AMEX, while THTX trades at $3.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APUS currently has a P/E ratio of -0.25, whereas THTX's P/E ratio is -28.83. In terms of profitability, APUS's ROE is -0.55%, compared to THTX's ROE of +0.17%. Regarding short-term risk, APUS is more volatile compared to THTX. This indicates higher risk in terms of short-term price fluctuations for APUS.Check THTX's competition here
Assertio Holdings, Inc. (NASDAQ: ASRT)
APUS vs ASRT Comparison July 2026
Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APUS stands at 861.3K. In comparison, ASRT has a market cap of 151.9M. Regarding current trading prices, APUS is priced at $0.66 on the AMEX, while ASRT trades at $23.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APUS currently has a P/E ratio of -0.25, whereas ASRT's P/E ratio is -7.10. In terms of profitability, APUS's ROE is -0.55%, compared to ASRT's ROE of -0.39%. Regarding short-term risk, APUS is more volatile compared to ASRT. This indicates higher risk in terms of short-term price fluctuations for APUS.Check ASRT's competition here
Cardiol Therapeutics Inc. (NASDAQ: CRDL)
APUS vs CRDL Comparison July 2026
Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APUS stands at 861.3K. In comparison, CRDL has a market cap of 147.5M. Regarding current trading prices, APUS is priced at $0.66 on the AMEX, while CRDL trades at $1.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APUS currently has a P/E ratio of -0.25, whereas CRDL's P/E ratio is -4.56. In terms of profitability, APUS's ROE is -0.55%, compared to CRDL's ROE of -2.29%. Regarding short-term risk, APUS is more volatile compared to CRDL. This indicates higher risk in terms of short-term price fluctuations for APUS.Check CRDL's competition here
Organigram Global Inc. (NASDAQ: OGI)
APUS vs OGI Comparison July 2026
Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APUS stands at 861.3K. In comparison, OGI has a market cap of 133M. Regarding current trading prices, APUS is priced at $0.66 on the AMEX, while OGI trades at $0.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APUS currently has a P/E ratio of -0.25, whereas OGI's P/E ratio is -3.63. In terms of profitability, APUS's ROE is -0.55%, compared to OGI's ROE of -0.07%. Regarding short-term risk, APUS is more volatile compared to OGI. This indicates higher risk in terms of short-term price fluctuations for APUS.Check OGI's competition here
Societal CDMO, Inc. (NASDAQ: SCTL)
APUS vs SCTL Comparison July 2026
Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APUS stands at 861.3K. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, APUS is priced at $0.66 on the AMEX, while SCTL trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APUS currently has a P/E ratio of -0.25, whereas SCTL's P/E ratio is -7.86. In terms of profitability, APUS's ROE is -0.55%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, APUS is more volatile compared to SCTL. This indicates higher risk in terms of short-term price fluctuations for APUS.Check SCTL's competition here
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX)
APUS vs CPIX Comparison July 2026
Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APUS stands at 861.3K. In comparison, CPIX has a market cap of 106.6M. Regarding current trading prices, APUS is priced at $0.66 on the AMEX, while CPIX trades at $7.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APUS currently has a P/E ratio of -0.25, whereas CPIX's P/E ratio is -39.53. In terms of profitability, APUS's ROE is -0.55%, compared to CPIX's ROE of -0.29%. Regarding short-term risk, APUS is less volatile compared to CPIX. This indicates lower risk in terms of short-term price fluctuations for APUS.Check CPIX's competition here
Procaps Group S.A. (NASDAQ: PROC)
APUS vs PROC Comparison July 2026
Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APUS stands at 861.3K. In comparison, PROC has a market cap of 102.1M. Regarding current trading prices, APUS is priced at $0.66 on the AMEX, while PROC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APUS currently has a P/E ratio of -0.25, whereas PROC's P/E ratio is 1.53. In terms of profitability, APUS's ROE is -0.55%, compared to PROC's ROE of -2.22%. Regarding short-term risk, APUS is more volatile compared to PROC. This indicates higher risk in terms of short-term price fluctuations for APUS.Check PROC's competition here
OptiNose, Inc. (NASDAQ: OPTN)
APUS vs OPTN Comparison July 2026
Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APUS stands at 861.3K. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, APUS is priced at $0.66 on the AMEX, while OPTN trades at $9.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APUS currently has a P/E ratio of -0.25, whereas OPTN's P/E ratio is -4.42. In terms of profitability, APUS's ROE is -0.55%, compared to OPTN's ROE of +0.34%. Regarding short-term risk, APUS is more volatile compared to OPTN. This indicates higher risk in terms of short-term price fluctuations for APUS.Check OPTN's competition here
Zomedica Corp. (AMEX: ZOM)
APUS vs ZOM Comparison July 2026
Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APUS stands at 861.3K. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, APUS is priced at $0.66 on the AMEX, while ZOM trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APUS currently has a P/E ratio of -0.25, whereas ZOM's P/E ratio is -1.62. In terms of profitability, APUS's ROE is -0.55%, compared to ZOM's ROE of -0.19%. Regarding short-term risk, APUS is more volatile compared to ZOM. This indicates higher risk in terms of short-term price fluctuations for APUS.Check ZOM's competition here
Upexi, Inc. (NASDAQ: GRVI)
APUS vs GRVI Comparison July 2026
Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APUS stands at 861.3K. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, APUS is priced at $0.66 on the AMEX, while GRVI trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APUS currently has a P/E ratio of -0.25, whereas GRVI's P/E ratio is 26.05. In terms of profitability, APUS's ROE is -0.55%, compared to GRVI's ROE of -2.54%. Regarding short-term risk, APUS is more volatile compared to GRVI. This indicates higher risk in terms of short-term price fluctuations for APUS.Check GRVI's competition here
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE)
APUS vs ZYNE Comparison July 2026
Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APUS stands at 861.3K. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, APUS is priced at $0.66 on the AMEX, while ZYNE trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APUS currently has a P/E ratio of -0.25, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, APUS's ROE is -0.55%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, APUS is more volatile compared to ZYNE. This indicates higher risk in terms of short-term price fluctuations for APUS.Check ZYNE's competition here
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT)
APUS vs ZYBT Comparison July 2026
Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APUS stands at 861.3K. In comparison, ZYBT has a market cap of 66.8M. Regarding current trading prices, APUS is priced at $0.66 on the AMEX, while ZYBT trades at $1.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APUS currently has a P/E ratio of -0.25, whereas ZYBT's P/E ratio is -6.41. In terms of profitability, APUS's ROE is -0.55%, compared to ZYBT's ROE of -0.27%. Regarding short-term risk, APUS is less volatile compared to ZYBT. This indicates lower risk in terms of short-term price fluctuations for APUS.Check ZYBT's competition here
Silver Spike Investment Corp. (NASDAQ: SSIC)
APUS vs SSIC Comparison July 2026
Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APUS stands at 861.3K. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, APUS is priced at $0.66 on the AMEX, while SSIC trades at $10.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APUS currently has a P/E ratio of -0.25, whereas SSIC's P/E ratio is 11.93. In terms of profitability, APUS's ROE is -0.55%, compared to SSIC's ROE of +0.00%. Regarding short-term risk, APUS is more volatile compared to SSIC. This indicates higher risk in terms of short-term price fluctuations for APUS.Check SSIC's competition here
The Valens Company Inc. (NASDAQ: VLNS)
APUS vs VLNS Comparison July 2026
Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APUS stands at 861.3K. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, APUS is priced at $0.66 on the AMEX, while VLNS trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APUS currently has a P/E ratio of -0.25, whereas VLNS's P/E ratio is -1.03. In terms of profitability, APUS's ROE is -0.55%, compared to VLNS's ROE of N/A. Regarding short-term risk, APUS is more volatile compared to VLNS. This indicates higher risk in terms of short-term price fluctuations for APUS.Check VLNS's competition here
DURECT Corporation (NASDAQ: DRRX)
APUS vs DRRX Comparison July 2026
Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APUS stands at 861.3K. In comparison, DRRX has a market cap of 59.3M. Regarding current trading prices, APUS is priced at $0.66 on the AMEX, while DRRX trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APUS currently has a P/E ratio of -0.25, whereas DRRX's P/E ratio is -4.44. In terms of profitability, APUS's ROE is -0.55%, compared to DRRX's ROE of -1.40%. Regarding short-term risk, APUS is more volatile compared to DRRX. This indicates higher risk in terms of short-term price fluctuations for APUS.Check DRRX's competition here
BGM Group Ltd. (NASDAQ: BGM)
APUS vs BGM Comparison July 2026
Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APUS stands at 861.3K. In comparison, BGM has a market cap of 56.4M. Regarding current trading prices, APUS is priced at $0.66 on the AMEX, while BGM trades at $0.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APUS currently has a P/E ratio of -0.25, whereas BGM's P/E ratio is -0.97. In terms of profitability, APUS's ROE is -0.55%, compared to BGM's ROE of -0.03%. Regarding short-term risk, APUS is more volatile compared to BGM. This indicates higher risk in terms of short-term price fluctuations for APUS.Check BGM's competition here
InterCure Ltd. (NASDAQ: INCR)
APUS vs INCR Comparison July 2026
Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APUS stands at 861.3K. In comparison, INCR has a market cap of 54.9M. Regarding current trading prices, APUS is priced at $0.66 on the AMEX, while INCR trades at $0.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APUS currently has a P/E ratio of -0.25, whereas INCR's P/E ratio is -2.22. In terms of profitability, APUS's ROE is -0.55%, compared to INCR's ROE of -0.09%. Regarding short-term risk, APUS is more volatile compared to INCR. This indicates higher risk in terms of short-term price fluctuations for APUS.Check INCR's competition here
Jupiter Wellness, Inc. (NASDAQ: JUPW)
APUS vs JUPW Comparison July 2026
Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APUS stands at 861.3K. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, APUS is priced at $0.66 on the AMEX, while JUPW trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APUS currently has a P/E ratio of -0.25, whereas JUPW's P/E ratio is -2.41. In terms of profitability, APUS's ROE is -0.55%, compared to JUPW's ROE of -1.94%. Regarding short-term risk, APUS is less volatile compared to JUPW. This indicates lower risk in terms of short-term price fluctuations for APUS.Check JUPW's competition here
Qilian International Holding Group Limited (NASDAQ: QLI)
APUS vs QLI Comparison July 2026
Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APUS stands at 861.3K. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, APUS is priced at $0.66 on the AMEX, while QLI trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APUS currently has a P/E ratio of -0.25, whereas QLI's P/E ratio is -4.92. In terms of profitability, APUS's ROE is -0.55%, compared to QLI's ROE of -0.16%. Regarding short-term risk, APUS is more volatile compared to QLI. This indicates higher risk in terms of short-term price fluctuations for APUS.Check QLI's competition here
Incannex Healthcare Limited (NASDAQ: IXHL)
APUS vs IXHL Comparison July 2026
Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APUS stands at 861.3K. In comparison, IXHL has a market cap of 37.3M. Regarding current trading prices, APUS is priced at $0.66 on the AMEX, while IXHL trades at $3.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APUS currently has a P/E ratio of -0.25, whereas IXHL's P/E ratio is -4.55. In terms of profitability, APUS's ROE is -0.55%, compared to IXHL's ROE of -0.92%. Regarding short-term risk, APUS is more volatile compared to IXHL. This indicates higher risk in terms of short-term price fluctuations for APUS.Check IXHL's competition here
HEXO Corp. (NASDAQ: HEXO)
APUS vs HEXO Comparison July 2026
Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APUS stands at 861.3K. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, APUS is priced at $0.66 on the AMEX, while HEXO trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APUS currently has a P/E ratio of -0.25, whereas HEXO's P/E ratio is -0.26. In terms of profitability, APUS's ROE is -0.55%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, APUS is more volatile compared to HEXO. This indicates higher risk in terms of short-term price fluctuations for APUS.Check HEXO's competition here
Talphera, Inc. (NASDAQ: TLPH)
APUS vs TLPH Comparison July 2026
Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APUS stands at 861.3K. In comparison, TLPH has a market cap of 26.5M. Regarding current trading prices, APUS is priced at $0.66 on the AMEX, while TLPH trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APUS currently has a P/E ratio of -0.25, whereas TLPH's P/E ratio is -4.16. In terms of profitability, APUS's ROE is -0.55%, compared to TLPH's ROE of -0.93%. Regarding short-term risk, APUS is more volatile compared to TLPH. This indicates higher risk in terms of short-term price fluctuations for APUS.Check TLPH's competition here
Rockwell Medical, Inc. (NASDAQ: RMTI)
APUS vs RMTI Comparison July 2026
Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APUS stands at 861.3K. In comparison, RMTI has a market cap of 25.4M. Regarding current trading prices, APUS is priced at $0.66 on the AMEX, while RMTI trades at $6.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APUS currently has a P/E ratio of -0.25, whereas RMTI's P/E ratio is -6.12. In terms of profitability, APUS's ROE is -0.55%, compared to RMTI's ROE of -0.15%. Regarding short-term risk, APUS is more volatile compared to RMTI. This indicates higher risk in terms of short-term price fluctuations for APUS.Check RMTI's competition here
Cyclo Therapeutics, Inc. (NASDAQ: CYTH)
APUS vs CYTH Comparison July 2026
Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APUS stands at 861.3K. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, APUS is priced at $0.66 on the AMEX, while CYTH trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APUS currently has a P/E ratio of -0.25, whereas CYTH's P/E ratio is -0.80. In terms of profitability, APUS's ROE is -0.55%, compared to CYTH's ROE of -7.30%. Regarding short-term risk, APUS is more volatile compared to CYTH. This indicates higher risk in terms of short-term price fluctuations for APUS.Check CYTH's competition here
TherapeuticsMD, Inc. (NASDAQ: TXMD)
APUS vs TXMD Comparison July 2026
Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APUS stands at 861.3K. In comparison, TXMD has a market cap of 23.4M. Regarding current trading prices, APUS is priced at $0.66 on the AMEX, while TXMD trades at $2.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APUS currently has a P/E ratio of -0.25, whereas TXMD's P/E ratio is 102.90. In terms of profitability, APUS's ROE is -0.55%, compared to TXMD's ROE of +0.01%. Regarding short-term risk, APUS is more volatile compared to TXMD. This indicates higher risk in terms of short-term price fluctuations for APUS.Check TXMD's competition here
Evoke Pharma, Inc. (NASDAQ: EVOK)
APUS vs EVOK Comparison July 2026
Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APUS stands at 861.3K. In comparison, EVOK has a market cap of 18.9M. Regarding current trading prices, APUS is priced at $0.66 on the AMEX, while EVOK trades at $11.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APUS currently has a P/E ratio of -0.25, whereas EVOK's P/E ratio is -7.97. In terms of profitability, APUS's ROE is -0.55%, compared to EVOK's ROE of -0.89%. Regarding short-term risk, APUS is more volatile compared to EVOK. This indicates higher risk in terms of short-term price fluctuations for APUS.Check EVOK's competition here
Aytu BioPharma, Inc. (NASDAQ: AYTU)
APUS vs AYTU Comparison July 2026
Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APUS stands at 861.3K. In comparison, AYTU has a market cap of 17.5M. Regarding current trading prices, APUS is priced at $0.66 on the AMEX, while AYTU trades at $2.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APUS currently has a P/E ratio of -0.25, whereas AYTU's P/E ratio is -1.13. In terms of profitability, APUS's ROE is -0.55%, compared to AYTU's ROE of -1.49%. Regarding short-term risk, APUS is more volatile compared to AYTU. This indicates higher risk in terms of short-term price fluctuations for APUS.Check AYTU's competition here
Optimi Health Corp. (NASDAQ: OPTH)
APUS vs OPTH Comparison July 2026
Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APUS stands at 861.3K. In comparison, OPTH has a market cap of 15.1M. Regarding current trading prices, APUS is priced at $0.66 on the AMEX, while OPTH trades at $4.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APUS currently has a P/E ratio of -0.25, whereas OPTH's P/E ratio is -17.16. In terms of profitability, APUS's ROE is -0.55%, compared to OPTH's ROE of -0.94%. Regarding short-term risk, APUS is more volatile compared to OPTH. This indicates higher risk in terms of short-term price fluctuations for APUS.Check OPTH's competition here
AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX)
APUS vs ACRX Comparison July 2026
Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APUS stands at 861.3K. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, APUS is priced at $0.66 on the AMEX, while ACRX trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APUS currently has a P/E ratio of -0.25, whereas ACRX's P/E ratio is -0.31. In terms of profitability, APUS's ROE is -0.55%, compared to ACRX's ROE of -0.93%. Regarding short-term risk, APUS is less volatile compared to ACRX. This indicates lower risk in terms of short-term price fluctuations for APUS.Check ACRX's competition here
Cosmos Health Inc. (NASDAQ: COSM)
APUS vs COSM Comparison July 2026
Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APUS stands at 861.3K. In comparison, COSM has a market cap of 13.2M. Regarding current trading prices, APUS is priced at $0.66 on the AMEX, while COSM trades at $0.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APUS currently has a P/E ratio of -0.25, whereas COSM's P/E ratio is -0.34. In terms of profitability, APUS's ROE is -0.55%, compared to COSM's ROE of -0.96%. Regarding short-term risk, APUS is more volatile compared to COSM. This indicates higher risk in terms of short-term price fluctuations for APUS.Check COSM's competition here
Biofrontera Inc. (NASDAQ: BFRIW)
APUS vs BFRIW Comparison July 2026
Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APUS stands at 861.3K. In comparison, BFRIW has a market cap of 11M. Regarding current trading prices, APUS is priced at $0.66 on the AMEX, while BFRIW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APUS currently has a P/E ratio of -0.25, whereas BFRIW's P/E ratio is -0.03. In terms of profitability, APUS's ROE is -0.55%, compared to BFRIW's ROE of -4.77%. Regarding short-term risk, APUS is more volatile compared to BFRIW. This indicates higher risk in terms of short-term price fluctuations for APUS.Check BFRIW's competition here
Agile Therapeutics, Inc. (NASDAQ: AGRX)
APUS vs AGRX Comparison July 2026
Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APUS stands at 861.3K. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, APUS is priced at $0.66 on the AMEX, while AGRX trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APUS currently has a P/E ratio of -0.25, whereas AGRX's P/E ratio is -0.89. In terms of profitability, APUS's ROE is -0.55%, compared to AGRX's ROE of +1.32%. Regarding short-term risk, APUS is more volatile compared to AGRX. This indicates higher risk in terms of short-term price fluctuations for APUS.Check AGRX's competition here
Neoleukin Therapeutics, Inc. (NASDAQ: NLTX)
APUS vs NLTX Comparison July 2026
Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APUS stands at 861.3K. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, APUS is priced at $0.66 on the AMEX, while NLTX trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APUS currently has a P/E ratio of -0.25, whereas NLTX's P/E ratio is -0.28. In terms of profitability, APUS's ROE is -0.55%, compared to NLTX's ROE of -0.38%. Regarding short-term risk, APUS is more volatile compared to NLTX. This indicates higher risk in terms of short-term price fluctuations for APUS.Check NLTX's competition here
Lannett Company, Inc. (NYSE: LCI)
APUS vs LCI Comparison July 2026
Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APUS stands at 861.3K. In comparison, LCI has a market cap of 7.4M. Regarding current trading prices, APUS is priced at $0.66 on the AMEX, while LCI trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APUS currently has a P/E ratio of -0.25, whereas LCI's P/E ratio is -0.04. In terms of profitability, APUS's ROE is -0.55%, compared to LCI's ROE of +1.66%. Regarding short-term risk, APUS is less volatile compared to LCI. This indicates lower risk in terms of short-term price fluctuations for APUS.Check LCI's competition here
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP)
APUS vs ADMP Comparison July 2026
Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APUS stands at 861.3K. In comparison, ADMP has a market cap of 7.3M. Regarding current trading prices, APUS is priced at $0.66 on the AMEX, while ADMP trades at $0.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APUS currently has a P/E ratio of -0.25, whereas ADMP's P/E ratio is -0.08. In terms of profitability, APUS's ROE is -0.55%, compared to ADMP's ROE of -2.09%. Regarding short-term risk, APUS is more volatile compared to ADMP. This indicates higher risk in terms of short-term price fluctuations for APUS.Check ADMP's competition here
Gelteq Limited Ordinary Shares (NASDAQ: GELS)
APUS vs GELS Comparison July 2026
Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APUS stands at 861.3K. In comparison, GELS has a market cap of 6.2M. Regarding current trading prices, APUS is priced at $0.66 on the AMEX, while GELS trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APUS currently has a P/E ratio of -0.25, whereas GELS's P/E ratio is -1.36. In terms of profitability, APUS's ROE is -0.55%, compared to GELS's ROE of -0.25%. Regarding short-term risk, APUS is less volatile compared to GELS. This indicates lower risk in terms of short-term price fluctuations for APUS.Check GELS's competition here
cbdMD, Inc. (AMEX: YCBD)
APUS vs YCBD Comparison July 2026
Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APUS stands at 861.3K. In comparison, YCBD has a market cap of 6M. Regarding current trading prices, APUS is priced at $0.66 on the AMEX, while YCBD trades at $0.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APUS currently has a P/E ratio of -0.25, whereas YCBD's P/E ratio is -1.40. In terms of profitability, APUS's ROE is -0.55%, compared to YCBD's ROE of -0.34%. Regarding short-term risk, APUS is more volatile compared to YCBD. This indicates higher risk in terms of short-term price fluctuations for APUS.Check YCBD's competition here
China Pharma Holdings, Inc. (AMEX: CPHI)
APUS vs CPHI Comparison July 2026
Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APUS stands at 861.3K. In comparison, CPHI has a market cap of 5.8M. Regarding current trading prices, APUS is priced at $0.66 on the AMEX, while CPHI trades at $1.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APUS currently has a P/E ratio of -0.25, whereas CPHI's P/E ratio is -2.83. In terms of profitability, APUS's ROE is -0.55%, compared to CPHI's ROE of -0.19%. Regarding short-term risk, APUS is less volatile compared to CPHI. This indicates lower risk in terms of short-term price fluctuations for APUS.Check CPHI's competition here
Mallinckrodt plc (AMEX: MNK)
APUS vs MNK Comparison July 2026
Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APUS stands at 861.3K. In comparison, MNK has a market cap of 4.5M. Regarding current trading prices, APUS is priced at $0.66 on the AMEX, while MNK trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APUS currently has a P/E ratio of -0.25, whereas MNK's P/E ratio is -0.44. In terms of profitability, APUS's ROE is -0.55%, compared to MNK's ROE of -0.26%. Regarding short-term risk, APUS is less volatile compared to MNK. This indicates lower risk in terms of short-term price fluctuations for APUS.Check MNK's competition here
Flora Growth Corp. (NASDAQ: FLGC)
APUS vs FLGC Comparison July 2026
Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APUS stands at 861.3K. In comparison, FLGC has a market cap of 4.2M. Regarding current trading prices, APUS is priced at $0.66 on the AMEX, while FLGC trades at $7.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APUS currently has a P/E ratio of -0.25, whereas FLGC's P/E ratio is -0.19. In terms of profitability, APUS's ROE is -0.55%, compared to FLGC's ROE of -2.70%. Regarding short-term risk, APUS is less volatile compared to FLGC. This indicates lower risk in terms of short-term price fluctuations for APUS.Check FLGC's competition here
Universe Pharmaceuticals Inc. (NASDAQ: UPC)
APUS vs UPC Comparison July 2026
Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APUS stands at 861.3K. In comparison, UPC has a market cap of 2.6M. Regarding current trading prices, APUS is priced at $0.66 on the AMEX, while UPC trades at $4.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APUS currently has a P/E ratio of -0.25, whereas UPC's P/E ratio is -0.51. In terms of profitability, APUS's ROE is -0.55%, compared to UPC's ROE of -0.07%. Regarding short-term risk, APUS is less volatile compared to UPC. This indicates lower risk in terms of short-term price fluctuations for APUS.Check UPC's competition here
PLx Pharma Inc. (NASDAQ: PLXP)
APUS vs PLXP Comparison July 2026
Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APUS stands at 861.3K. In comparison, PLXP has a market cap of 2.5M. Regarding current trading prices, APUS is priced at $0.66 on the AMEX, while PLXP trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APUS currently has a P/E ratio of -0.25, whereas PLXP's P/E ratio is -0.22. In terms of profitability, APUS's ROE is -0.55%, compared to PLXP's ROE of -1.66%. Regarding short-term risk, APUS is less volatile compared to PLXP. This indicates lower risk in terms of short-term price fluctuations for APUS.Check PLXP's competition here
Athenex, Inc. (NASDAQ: ATNX)
APUS vs ATNX Comparison July 2026
Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APUS stands at 861.3K. In comparison, ATNX has a market cap of 2.3M. Regarding current trading prices, APUS is priced at $0.66 on the AMEX, while ATNX trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APUS currently has a P/E ratio of -0.25, whereas ATNX's P/E ratio is -0.02. In terms of profitability, APUS's ROE is -0.55%, compared to ATNX's ROE of +0.22%. Regarding short-term risk, APUS is more volatile compared to ATNX. This indicates higher risk in terms of short-term price fluctuations for APUS.Check ATNX's competition here
RedHill Biopharma Ltd. (NASDAQ: RDHL)
APUS vs RDHL Comparison July 2026
Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APUS stands at 861.3K. In comparison, RDHL has a market cap of 2.2M. Regarding current trading prices, APUS is priced at $0.66 on the AMEX, while RDHL trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APUS currently has a P/E ratio of -0.25, whereas RDHL's P/E ratio is 0.14. In terms of profitability, APUS's ROE is -0.55%, compared to RDHL's ROE of +57.40%. Regarding short-term risk, APUS is more volatile compared to RDHL. This indicates higher risk in terms of short-term price fluctuations for APUS.Check RDHL's competition here
Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA)
APUS vs SNOA Comparison July 2026
Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APUS stands at 861.3K. In comparison, SNOA has a market cap of 2M. Regarding current trading prices, APUS is priced at $0.66 on the AMEX, while SNOA trades at $1.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APUS currently has a P/E ratio of -0.25, whereas SNOA's P/E ratio is -1.24. In terms of profitability, APUS's ROE is -0.55%, compared to SNOA's ROE of -0.88%. Regarding short-term risk, APUS is more volatile compared to SNOA. This indicates higher risk in terms of short-term price fluctuations for APUS.Check SNOA's competition here
Procaps Group, S.A. (NASDAQ: PROCW)
APUS vs PROCW Comparison July 2026
Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APUS stands at 861.3K. In comparison, PROCW has a market cap of 2M. Regarding current trading prices, APUS is priced at $0.66 on the AMEX, while PROCW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APUS currently has a P/E ratio of -0.25, whereas PROCW's P/E ratio is N/A. In terms of profitability, APUS's ROE is -0.55%, compared to PROCW's ROE of -2.22%. Regarding short-term risk, APUS is more volatile compared to PROCW. This indicates higher risk in terms of short-term price fluctuations for APUS.Check PROCW's competition here
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH)
APUS vs SHPH Comparison July 2026
Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APUS stands at 861.3K. In comparison, SHPH has a market cap of 1.8M. Regarding current trading prices, APUS is priced at $0.66 on the AMEX, while SHPH trades at $3.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APUS currently has a P/E ratio of -0.25, whereas SHPH's P/E ratio is -0.14. In terms of profitability, APUS's ROE is -0.55%, compared to SHPH's ROE of -4.08%. Regarding short-term risk, APUS is more volatile compared to SHPH. This indicates higher risk in terms of short-term price fluctuations for APUS.Check SHPH's competition here